Extremely excited and over the moon to have matched @BIDMC_IM @harvardmed !!! This would not have been possible without the incredible support of my exceptional mentors @DrChoueiri @VanAllenLab @BraunMDPhD Missing my parents.

Another @VanAllenLab @DanaFarber_GU collaboration with our friend @BraunMDPhD + many super stars like @Chrislabaki1 @eddy_saad @ZiadBakouny et al (all co-mentored @VanAllenLab)--we will unlock biomarkers of IO resistance in RCC, 1 step at a time. cc: @DanaFarber_GU @ImmunityCP

Here's our latest - a deep dive into myeloid mediated immunotherapy resistance in kidney cancer, pairing single cell meta-analysis with companion experiments (h/t @DrChoueiri + @BraunMDPhD collaborations) Congrats Kevin Bi et al! @DanaFarber @broadinstitute @ImmunityCP

Game-changing presentation by our one and only superstar @eddy_saad @bidmc_im: AI-based synthetic cohorts from 19k #BreastCancer patients offer a reliable way to facilitate data sharing in a privacy-safe manner #ESMO25 @myESMO Huge applications for clinical trial design and

Happening now #ESMO25: @eddy_saad delivers a fantastic presentation of his work on synthetic RWD and its applications in oncology! @DrChoueiri @BIDMC_IM

Congratulations @Clara__Steiner on a wonderful poster on transcriptomic predictors of metastatic organ tropism in RCC and for being selected for a Merit Travel Grant! @myESMO #ESMO25 @DrChoueiri @VincentWenxinXu

Novel and exciting data by @BernatzSimon! AI-graded thymic health from baseline CT predicts IO outcomes pan-cancer. high vs low → PFS HR 0.59; OS HR 0.56 after adjustment. Signal consistent across PD-L1/TMB strata. Future host-specific IO-marker? #ESMO25 #AI @myESMO

Stellar work by @ReneeSaliby characterizing the cytokine landscape in exceptional responders to immunotherapy. Congrats on the Merit Travel Grant! #ESMO25 @BraunMDPhD @DrChoueiri @YaleIMed

Bench to bedside hour with basic science & translational research session chaired by one and only @VanAllenLab & #OlivierMichielin: signals shaping next-gen trials. #ESMO25 @myESMO @DanaFarber @DanaFarberNews

1/ Now out in @Annals_Oncology! In patients with kidney cancer, a blood test for KIM-1 is prognostic and predictive for adjuvant immunotherapy. Amazing multi-institution collaboration @montypal @brian_rini @AlbigesL @Robert_Uzzo @genentech @robanche

🆕article in press: Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma @VincentWenxinXu @brian_rini https://t.co/9hLyZiOMkh

1/11 Pleased to share that our multi-institutional study “Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma” was published today. This represents the most comprehensive analysis of LCNEC to date. Grateful for the support of

JUST IN: (+) Phase 3 KEYNOTE-905 trial in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): EV+Pembro shows an EFS, pCR and OS benefit compared to radical cystectomy alone. a Potential new SOC (again). cc: @biospace https://t.co/qVaDh0I3GN

Come join us @MSKCancerCenter! You’ll work with @EdReznik and I on really cool science Please help spread the word @DrChoueiri @BraunMDPhD @srviswanathan @VanAllenLab @OncoAlert @Chrislabaki1 @ReneeSaliby @eddy_saad

Please check out our editorial just out in @NatRevUrol on a pragmatic approach to biomarkers for RCC! Many challenges, but with now some emerging promising biomarkers! @arihakimi @EdReznik @motzermd @MSKCancerCenter @MSK_DeptOfMed https://t.co/CaRdSBJP51

Just 1 week away! Please join me in #PMC2025 #CloserByTheMile. Fighting cancer is more important now than ever. 100% of all donations support cancer research at Dana-Farber Cancer Institute. https://t.co/dh4Cl6Ttxd

Breaking out of the group chat💥 Four years ago I was recovering from surgery and messaging my support system, the “chromophobe six”, about the lack of research, info, and community for #chRCC. There wasn’t a singled funded foundation grant for chRCC at the time. This evening I

Powerful words @CJSTRAV3 about the importance of research funding and continuous efforts, with the goal of improving patient outcomes @kidneycan #KCRS25

Great talk by @VincentWenxinXu regarding the major role of KIM-1 in guiding therapeutic decision-making in #RCC @kidneycan #KCRS25

Bryan Lewis @kidneycan with a moving and touching speech at the opening ceremony of #KCRS25

And we're off! #KCRS25 begins with an important session on variant histologies of RCC, with @BradMcG04 giving an overview of papillary RCC @KidneyCancer